Abstract：
UNASSIGNED: The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to conduct a systematic review and meta-analysis, to assess the efficacy and safety of subcutaneous rituximab to NHL.
UNASSIGNED: A full-scale search was carried out based on the set search terms in PubMed, Web of Science, Embase and Cochrane CENTRAL until 12 October 2022 to identify relevant studies of subcutaneous rituximab for NHL. The efficacy and safety outcomes included complete response (CR) plus unconfirmed complete response (CRu), adverse events (AEs), grade ≥3 AEs, serious adverse events (SAEs), administration-related reactions (ARRs), adverse reaction rates.
UNASSIGNED: From a total of 758 studies, 9 trials were eligible. The CR/CRu of patients with NHL receiving SC rituximab was 57%, 55% for Diffuse large B-cell lymphoma (DLBCL) and 54% for Follicular lymphoma (FL). The meta-analysis performed on safety demonstrated that AEs of NHL patients with SC rituximab was 85%, grade ≥3 AEs was 38%, SAE was 27% and ARR was 33%. The result also showed that SC rituximab had a high risk of neutropenia and nausea.
UNASSIGNED: For NHL patients, there is no significant difference in the efficacy between subcutaneous rituximab and conventional therapy, while subcutaneous injection can shorten exposure time in the hospital and reduce the risk of infection.
UNASSIGNED: A full-scale search was carried out based on the set search terms in PubMed, Web of Science, Embase and Cochrane CENTRAL until 12 October 2022 to identify relevant studies of subcutaneous rituximab for NHL. The efficacy and safety outcomes included complete response (CR) plus unconfirmed complete response (CRu), adverse events (AEs), grade ≥3 AEs, serious adverse events (SAEs), administration-related reactions (ARRs), adverse reaction rates.
UNASSIGNED: From a total of 758 studies, 9 trials were eligible. The CR/CRu of patients with NHL receiving SC rituximab was 57%, 55% for Diffuse large B-cell lymphoma (DLBCL) and 54% for Follicular lymphoma (FL). The meta-analysis performed on safety demonstrated that AEs of NHL patients with SC rituximab was 85%, grade ≥3 AEs was 38%, SAE was 27% and ARR was 33%. The result also showed that SC rituximab had a high risk of neutropenia and nausea.
UNASSIGNED: For NHL patients, there is no significant difference in the efficacy between subcutaneous rituximab and conventional therapy, while subcutaneous injection can shorten exposure time in the hospital and reduce the risk of infection.
摘要：
■皮下（SC）利妥昔单抗对非霍奇金淋巴瘤（NHL）的疗效和安全性的作用还不够明确。本研究的目的是进行系统评价和荟萃分析，评估皮下利妥昔单抗治疗NHL的疗效和安全性。
■根据PubMed中的设置搜索词进行了全面搜索，WebofScience,Embase和CochraneCENTRAL至2022年10月12日，以确定皮下利妥昔单抗治疗NHL的相关研究。疗效和安全性结果包括完全缓解（CR）加上未确认的完全缓解（CRu），不良事件（AE），≥3级不良事件，严重不良事件（SAE），给药相关反应（ARR），不良反应发生率。
■在总共758项研究中，9项试验合格。接受SC利妥昔单抗的NHL患者的CR/CRu为57％，弥漫性大B细胞淋巴瘤（DLBCL）占55％，滤泡性淋巴瘤（FL）占54％。对安全性进行的荟萃分析表明，使用SC利妥昔单抗的NHL患者的AE为85％，≥3级不良事件发生率为38%，SAE为27%,ARR为33%。结果还显示SC利妥昔单抗具有中性粒细胞减少症和恶心的高风险。
■对于NHL患者，利妥昔单抗与常规治疗的疗效无显著差异,而皮下注射可以缩短在医院的暴露时间，降低感染风险。
■根据PubMed中的设置搜索词进行了全面搜索，WebofScience,Embase和CochraneCENTRAL至2022年10月12日，以确定皮下利妥昔单抗治疗NHL的相关研究。疗效和安全性结果包括完全缓解（CR）加上未确认的完全缓解（CRu），不良事件（AE），≥3级不良事件，严重不良事件（SAE），给药相关反应（ARR），不良反应发生率。
■在总共758项研究中，9项试验合格。接受SC利妥昔单抗的NHL患者的CR/CRu为57％，弥漫性大B细胞淋巴瘤（DLBCL）占55％，滤泡性淋巴瘤（FL）占54％。对安全性进行的荟萃分析表明，使用SC利妥昔单抗的NHL患者的AE为85％，≥3级不良事件发生率为38%，SAE为27%,ARR为33%。结果还显示SC利妥昔单抗具有中性粒细胞减少症和恶心的高风险。
■对于NHL患者，利妥昔单抗与常规治疗的疗效无显著差异,而皮下注射可以缩短在医院的暴露时间，降低感染风险。
